- Home
- EWTX vs CRTO Comparison
EWTX vs CRTO Comparison
Compare EWTX & CRTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- CRTO
- Stock Information
- Founded
- EWTX 2017
- CRTO 2005
- Country
- EWTX United States
- CRTO France
- Employees
- EWTX N/A
- CRTO N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- CRTO Advertising
- Sector
- EWTX Health Care
- CRTO Consumer Discretionary
- Exchange
- EWTX Nasdaq
- CRTO Nasdaq
- Market Cap
- EWTX 1.5B
- CRTO 1.2B
- IPO Year
- EWTX 2021
- CRTO 2013
- Fundamental
- Price
- EWTX $15.57
- CRTO $23.33
- Analyst Decision
- EWTX Buy
- CRTO Buy
- Analyst Count
- EWTX 9
- CRTO 9
- Target Price
- EWTX $39.89
- CRTO $39.11
- AVG Volume (30 Days)
- EWTX 782.1K
- CRTO 300.1K
- Earning Date
- EWTX 08-07-2025
- CRTO 10-29-2025
- Dividend Yield
- EWTX N/A
- CRTO N/A
- EPS Growth
- EWTX N/A
- CRTO 44.35
- EPS
- EWTX N/A
- CRTO 2.38
- Revenue
- EWTX N/A
- CRTO $1,946,032,000.00
- Revenue This Year
- EWTX N/A
- CRTO N/A
- Revenue Next Year
- EWTX N/A
- CRTO $2.19
- P/E Ratio
- EWTX N/A
- CRTO $9.83
- Revenue Growth
- EWTX N/A
- CRTO N/A
- 52 Week Low
- EWTX $10.60
- CRTO $22.43
- 52 Week High
- EWTX $38.12
- CRTO $47.27
- Technical
- Relative Strength Index (RSI)
- EWTX 64.68
- CRTO 44.74
- Support Level
- EWTX $13.93
- CRTO $22.83
- Resistance Level
- EWTX $15.12
- CRTO $25.24
- Average True Range (ATR)
- EWTX 0.71
- CRTO 0.73
- MACD
- EWTX 0.10
- CRTO -0.08
- Stochastic Oscillator
- EWTX 90.29
- CRTO 20.91
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.